Table 2.
Association of PLR with the clinical characteristics of patients with cervical cancer.
| Variable | PLR (High) | PLR (Low) | X2 | P |
|---|---|---|---|---|
| Age (year) | ||||
| <50 year | 22 (52.40%) | 39 (57.40%) | 0.26 | 0.61 |
| ≥50 year | 20 (47.60%) | 29 (42.60%) | ||
| FIGO stage | ||||
| I + II | 16 (38.10%) | 36 (52.90%) | 5.51 | 0.169 |
| III + IV | 26 (61.90%) | 32 (47.10%) | ||
| Histological type | ||||
| SCC | 33 (78.60%) | 64 (94.10%) | 6.02 | 0.014 |
| Non-SCC | 9 (21.40%) | 4 (5.90%) | ||
| Lymph node metastasis | ||||
| Negative | 16 (38.10%) | 41 (60.30%) | 4.27 | 0.039 |
| Positive | 26 (61.90%) | 27 (39.70%) | ||
| Maximum tumour size (cm) | ||||
| >4 cm | 25 (59.50%) | 40 (58.80%) | 0.05 | 0.94 |
| ≤4 cm | 17 (40.50%) | 28 (41.20%) | ||
| Prognosis | ||||
| Effective | 20 (47.60%) | 53 (77.90%) | 9.379 | 0.001 |
| Ineffective | 22 (52.40%) | 15 (22.10%) |
PLR, platelet-to-lymphocyte ratio; FIGO, International Federation of Gynaecology and Obstetrics; SCC, squamous cell carcinoma.